TTrialPathMatch Me to Trials
← Back to trials
RecruitingDrug AllergyCephalosporin AllergyDrug Hypersensitivity

Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing

Eligible age

18–70 yrs

Accepts

All genders

Locations

6 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

Cephalosporin antibiotics are commonly used but can result in allergic reactions and anaphylaxis. There is no clear diagnostic approach for cephalosporin-allergic patients, and guidance for the use of other antibiotics in allergic patients is based on side chain chemical similarity and limited skin testing evidence. This project includes a clinical trial and mechanistic studies to optimize the approach to cephalosporin allergy and advance future diagnostics.

Sponsor: Massachusetts General Hospital

You may qualify if…

  • ✓ 1. Age 18-70 years old.
  • ✓ 2. Reaction history consistent with a potential immediate hypersensitivity reaction (pruritus, urticaria, erythema, angioedema, bronchospasm, wheezing, shortness of breath, anaphylaxis, or hypotension) to cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime.
  • ✓ 3. English speaking or non-English speaking with translation services available.

You may not qualify if…

  • ✕ 1. Severe concomitant medical condition (e.g., unstable coronary artery disease, congestive heart failure, severe chronic obstructive pulmonary disease, poorly controlled asthma, chronic renal failure, cirrhosis, or end-stage liver disease.)
  • ✕ 2. History of Clostridioides difficile infection
  • ✕ 3. Chronic spontaneous urticaria or systemic mastocytosis
  • ✕ 4. Incident reaction required cardiopulmonary resuscitation
  • ✕ 5. Reaction to 2 or more cephalosporin antibiotics
  • ✕ 6. Active infection or antibiotic treatment within 7 days
  • ✕ 7. Treatment with systemic antihistamines or corticosteroids within 7 days
  • ✕ 8. Treatment with omalizumab or dupilumab within 60 days

Where it's recruiting

Arizona

Scottsdale

California

San Francisco

New York

Rochester

Tennessee

Nashville

Texas

Dallas

Source: ClinicalTrials.gov · NCT06406114 · last updated 2026-11-12

Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing · TrialPath